Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Catena Media’s board approves share buybacks

The board of directors of Catena Media plc (the “company”) has resolved to exercise the company’s mandate to buy back up to 7,039,215 shares of the company’s own ordinary shares following the authorisation granted at an extraordinary general meeting of shareholders on 14 July 2021 (the "EGM"). The board sees share buybacks as a way to enhance the company’s flexibility in distributing capital to shareholders and to promote more efficient capital usage. The board has also been authorised to approve the cancellation of repurchased shares at a later date. Purchases of own shares will take

Momentum is building with sales growth of 88.2%

April to June 2021 (Fourth Quarter) · Net sales in Q4 were SEK 16.0m, corresponding to a 88.2% increase compared with the same period in 2020 (SEK 8.5m). · Normalized EBITDA (EBITDA before non-recurring items and FX translation) was SEK -1.8m compared to the same period in 2020 (SEK -0.1m). · EBITDA of SEK -7.2m compared to the same period in 2020 (SEK -3.3m). · Net loss was SEK -10.1m compared with a loss in the same period in 2020 (SEK -5.8m). · Basic earnings per share(weighted) amounted to SEK -0.21 (SEK -0.57). · Operating cashflow in Q4 was SEK 0.1m which was

Nixu Corporation’s growth ambition for 2022-2025

Nixu Corporation Stock Exchange Release on September 13, 2021 at 8.00 AM EESTEuropean cybersecurity company, Nixu hosts a Capital Markets Day today, on September 13, 2021 in a virtual format. Simultaneously the company publishes its mid-term growth ambition. Nixu published its past growth ambition statement during fall 2019. Due to the volatile and unforeseeable business environment caused by the Covid-19 pandemic, the company decided to halt its growth ambition in spring 2020. Instead of growth, the focus was placed on business continuity of its operations for the duration of the

Vestas extends partnership with wpd for 50 MW order, featuring Taiwan’s largest onshore rotors

News release from Vestas Asia Pacific Singapore, 13 Sep 2021Vestas has secured a 50 MW order with German developer and operator of renewable energy projects, wpd AG, for three projects - Chuangwei 2, Leadway 2 and Hsinyuan wind farms in Taiwan.The Hsinyuan wind farm includes six V136-4.2 MW turbines with 112m towers, featuring the largest onshore turbine rotors in Taiwan, which will maximise energy production for the site’s medium wind conditions.  Chuangwei 2 and Leadway 2 wind farms will be installed with four and two V117-4.2 MW turbines with 91.5m towers, respectively. With

Cantargia: New positive interim results on nadunolimab combination therapy in NSCLC published in abstract for the annual ESMO Congress

Cantargia AB today announced the publication of an abstract disclosing novel clinical interim data from the CANFOUR study. The abstract was submitted in May 2021 for the upcoming ESMO Congress starting 16 September, 2021. In 15 non-small cell lung cancer (NSCLC) patients evaluated for efficacy, nadunolimab (CAN04) combined with gemcitabine/cisplatin showed an overall response rate (ORR) of 60%, a median duration of response (DOR) of 6.2 months and a median progression-free survival (PFS) of 8.2 months. All these efficacy parameters compare favorably to historical control data from gemcitabine/

Oncopeptides presents phase 3 OCEAN study results at the IMW meeting

STOCKHOLM — September 11, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today presents data from the phase 3 OCEAN study, a direct head to head comparison of the efficacy and safety of melflufen (INN melphalan flufenamide) plus dexamethasone and pomalidomide plus dexamethasone in patients with relapsed refractory multiple myeloma, (RRMM), who are refractory to lenalidomide and have received 2-4 prior lines of therapy. The data was presented today by Fredrik Schjesvold,

UK's Best 10 New Casino Sites Revealed

Looking for a safe and exciting online casino? Here are the UK’s 10 best new casino sites to check out in 2021!If you are passionate about playing online casino games, you are not the only one. Over 40% of the population participates in casino games, and the Covid-19 pandemic has boosted the percentage of people playing online gambling games, which reached 25% in 2021 . In turn, the online gambling industry is working hard to meet the changing

SMART WIRES RECEIVES ORDER OF $23 - 20 million dollars FROM ISA TRANSELCA FOR PROJECT IN COLOMBIA

Smart Wires Technology Ltd (“Smart Wires”) has received a Purchase Order from ISA Transelca for a grid expansion project in the Guajira – Cesar – Magdalena (GCM) region: FACTS devices to be installed in the Guajira – Santa Marta and Termocol (Bonda) – Santa Marta 220 kV circuits referenced in the Plan de Expansión de Referencia de Generación Transmisión 2020 – 2034 issued by the national planning agency (Unidad de Planeación Minero Energética) of the Energy and Mines Ministry in Colombia. The order will have a net revenue of approximately $23.3 – 20.0 million dollars and with energization

Selvaag Bolig ASA: Mandatory notification of trades by primary insiders

Kristin Mill Lien Selvaag, close associate of primary insider Olav H. Selvaag, purchased 100 shares on 10. September 2021. The shares were purchased at an average at a price of NOK 58,70. Following this transaction, Kristin Lien Selvaag owns 50 099 shares in Selvaag Bolig ASA. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 10.09.2021

ALEXANDRIA PANKKIIRILIIKE OYJ NOTIFICATION 10.09.2021 at 18:30 EEST ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 10.09.2021 Date 10.09.2021Exchange transaction BuyShare class ALEXAmount 869Average price/share 8.7054 EURHighest price/share 8.7100 EURLowest price/share 8.7000 EURTotal price 7,564.99 EUR The shares held by Alexandria Pankkiiriliike Oyj on 10.09.2021: ALEX 15,604   On behalf of Alexandria Pankkiiriliike Oyj  Skandinaviska Enskilda Banken AB (Publ)

#21-301 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

New data presented at MDS Congress of ABBV-0805 in Parkinson’s disease

Stockholm, September 10, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will present new preclinical data for the investigational anti-α-synuclein antibody ABBV-0805 at the International Congress of Parkinson’s disease and movement disorders® (MDS), held virtually September 17 to 22, 2021. The presentation, which has been selected as a Top Abstract, includes data showing ABBV-0805’s ability to selectively target soluble toxic α-synuclein aggregates.BioArctic will present one abstract at the congress, focusing on the preclinical findings that continue to support ABBV-0805 for

Notification of Major Holdings in Catena Media plc

Catena Media plc (the "Company") hereby announces that it has on 10 September 2021 received a notification from Alcur Fonder AB, with registered office in Stockholm, Sweden. The notification is with regards to an acquisition or disposal of shares and voting rights in the Company (the "Notification") made by Alcur Fonder AB. The Notification indicates that Alcur Fonder AB, as of 8 September 2021, holds 7.26% of the shares and voting rights in the Company. The relevant chain of controlled undertakings can be found in the Notification, which can be found on the Company's website: https://

Aker Solutions Wins Topside Modification Contract for ConocoPhillips’ Tommeliten Alpha Development

September 10, 2021 – Aker Solutions has been awarded a large[1] topside modification contract by ConocoPhillips Skandinavia AS for Tommeliten Alpha, offshore Norway. Combined with previous subsea contracts for this field development, the contract award means Aker Solutions has been assigned an integrated responsibility for this field development.The topside modification contract award follows final investment decision by the license partners and the completion of the front-end engineering and design (FEED) work, awarded in October 2020 

Online Casinos in Thailand: 10 Best Real Money Casino Sites for Thai Players

While you are staying in Thailand, you may wonder about their existing gambling acts and popular online casino games. There are no casinos in Thailand because it is illegal to gamble in Thailand. The history of gambling in Thailand began way before. That’s why many Thai locals are avid gamblers. Although there are no land-based casinos that you can visit, there are many offshore online casinos that are available for everyone globally. Unfortunately, not all casinos are created equal and choosing the best online casino in Thailand can be overwhelming. Fortunately, we’ve done the heavy-

Diamyd Medical changes date for publication of year-end report

Diamyd Medical AB's year-end report for the financial year 2020/2021 will due to the directed share issue announced on September 10, be published on Wednesday 13 October 2021 instead of 6 October 2021 as previously announced.   About Diamyd Medical Diamyd Medical develops precision medicine therapies for type 1 diabetes. The diabetes vaccine Diamyd[®] is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s

European Commission approves internal injection of capital

The European Commission has today announced that it approves the internal injection of capital from PostNord Group AB to Post Denmark of DKK 2.3 billion. The injection took place in 2018 and 2019.“The approval decision is both welcome and gratifying. It’s positive that the Commission shares our view that the internal injection has been granted in accordance with market conditions and thus does not constitute state aid. I’m also pleased with the recent improvement in the Group’s results and the fact that we are now financially strong, which means that we can continue to invest in PostNord’s

Results from first comparative study with the Episealer® Knee implant accepted for publication

Episurf Medical (Nasdaq: EPIS B) today announces that a manuscript with results from a study with the title “Patient specific resurfacing implant knee surgery in subjects with early osteoarthritis results in medial pivot and lateral femoral rollback during flexion: a retrospective pilot study” by P. Moewis, R. Kaiser, A. Trepczynski, C. von Tycowicz, L. Krahl, A. Ilg, J. Holz, and G. N. Duda, performed at Charité University Hospital, Berlin, Germany, in collaboration with OrthoCentrum Hamburg and Zuse Institute Berlin, has been accepted for publication in the peer-reviewed scientific

Dentalum acquires Stångå Tandklinik and Svartå Tandklinik in Östergötland

Dentalum expands into Östergötland through the acquisitions of Stångå Tandklinik in Linköping and Svartå Tandklinik in Mjölby. With these two new acquisitions, Dentalum consists of 18 clinics, operating in seven regions in Sweden.On September 27, 2021 Dentalum will enter into a partnership with Jon Granath and his staff at Stångå Tandklinik and Svartå Tandklinik. Stångå Tandklinik in Linköping was established in 2011 and Svartå Tandklinik was established during Q4 of 2020. The clinics mainly offer general dentistry, treatments for sleep apnea, and a range of aesthetic treatments such as

Decisions taken by Adapteo Plc's Extraordinary General Meeting

Adapteo Plc – Regulatory Press Release – 10 September 2021 at 2 pm CEST Adapteo Plc's ("Adapteo") Extraordinary General Meeting ("EGM") was held today on 10 September 2021 in Vantaa. The EGM made the following resolutions. Amendment of the Articles of Association The EGM resolved to amend Section 4 of the Articles of association to read as follows: "4 Management of the company The Board of Directors shall consist of four (4) to eight (8) members. The term of the members of the Board of Directors shall expire at the end of the next Annual General Meeting of Shareholders

Amicogen Inc enters into agreement to divest its ownership in Bio-Works

Amicogen Inc. has entered into an agreement to divest its ownership in Bio-Works Technologies AB (BIOWKS.ST). Amicogen's entire holding of 3,007,896 shares was sold today at 12:03:42 CET in a transaction brokered by Erik Penser Bank for a price of 15.75 SEK. As of June 30, 2021, Amicogen Inc. was Bio-Works' second largest shareholder. The block was primarily sold to Nortal Investments AB and Calyptra AB. As of June 30, 2021, Nortal Investments AB was Bio-Works largest shareholder, owning 4,119,885 shares, or 13.6% of the company.  Dr. Shin, CEO of Amicogen Inc., stated “Amicogen was an

Cantargia receives regulatory approval to start CESTAFOUR clinical study with nadunolimab in combination with chemotherapy

Cantargia AB today announced approval to start the phase I/II clinical study CESTAFOUR by the regulatory authority and ethics committee in France. This study broadens the clinical development for nadunolimab (CAN04) to include biliary tract cancer (BTC), colorectal cancer (CRC) and late-stage non-small lung cancer (NSCLC) and will evaluate CAN04 in combination with standard of care chemotherapy. The study will be conducted at approximately 20 clinical centers in Europe and will include up to a total of 165 patients. The first patient is estimated to be enrolled in September/October 2021.

New date for publication of Crunchfish’s interim report for the third quarter 2021

Following the announcement of the rights issue of shares and warrants in Crunchfish AB, the Board of Directors of Crunchfish has decided to postpone the disclosure of the interim report for the third quarter 2021. New publication date is November 30, 2021.Crunchfish has, subject to approval by the Extraordinary General Meeting on September 16, 2021, resolved to carry out a rights issue of shares and warrants, with a subscription period between October 11-25, 2021. Hence, the Board of Directors has decided to postpone the disclosure of the interim report for the third quarter 2021 to

Cantargia completes patient recruitment to the phase IIa pancreatic cancer extension cohort in the CANFOUR study

Cantargia AB today announced that all planned 40 patients with advanced pancreatic cancer (PDAC) have started therapy in the phase IIa extension cohort in the CANFOUR study. Preliminary data from these patients confirm a good safety profile of nadunolimab (CAN04) combined with gemcitabine/nab-paclitaxel. Presentation of safety and efficacy data for the extension cohort is planned for the first half of 2022. Adding this group to the primary group previously analyzed, more than 70 patients with PDAC have now received CAN04 combined with chemotherapy. Preparations are ongoing for a randomized

There are no items matching the current filter
There are no more items matching the current filter
Back to top